메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Amcor Appoints Stephen R. Scherger as Executive Vice President and Chief Financial Officer

Michael Casamento to return home to Australia to be closer to his family on a full-time basis; Will leave the Company as a result, remaining in an advisory role until June 30, 2026 to support transition Company reaffirms Fiscal 2026 and first quarter Fiscal 2026 outlook ZURICH, Oct. 10, 2025 -- Amcor (NYSE: AMCR, ASX: AMC), a global leader in consumer packaging and dispensing solutions for Nutrition, Health, Beauty and Wellness, announced the appointment of Stephen R. Scherger as Executive Vice President and Chief Financial Officer, effective Nov. 10, 2025. Mr. Scherger succeeds
- 황정호 기자
- 2025-10-10 04:30
POMDOCTOR LIMITED Announces Closing of Initial Public Offering

GUANGZHOU, China, Oct. 10, 2025 -- POMDOCTOR LIMITED (Nasdaq: POM) (the "Company" or "POMDOCTOR"), a leading online medical services platform for chronic diseases in China, today announced the closing of its initial public offering (the "Offering") of 5,000,004 American Depositary Shares ("ADSs") at a public offering price of US$4.00 per ADS. Six ADSs represent one Class A ordinary share, par value US$0.0001 per share, of the Company. The ADSs began trading on Nasdaq Global Market on October 8, 2025 under the ticker symbol "POM." The Co
- 김갑성 기자
- 2025-10-10 04:05
Lifespan-Backed Algen Biotechnologies Partners with AstraZeneca to Advance AI Drug Discovery

NORWALK, Conn., Oct. 9, 2025 -- Lifespan Vision Ventures congratulates its portfolio company, Algen Biotechnologies, on the announcement of its multi-target research collaboration with AstraZeneca to advance AI-powered drug discovery in immunology. The partnership will combine Algen's cutting-edge functional genomics and machine learning platform with AstraZeneca's deep scientific expertise and global R&D capabilities. Together, the companies aim to identify and validate novel therapeutic targets for immune-mediated and inflammatory diseases, accelerating the discovery of n
- 김갑성 기자
- 2025-10-09 23:09
Kimberly-Clark Launches Enhanced Global Partnerships to Advance Essential Care for 24 Million Women and Girls

DALLAS, Oct. 9, 2025 -- Kimberly-Clark Corporation (NASDAQ: KMB) is deepening its commitment to advancing essential care for women and girls through four enhanced strategic, charitable partnerships. Through new programs with Baby2Baby, Plan International, Project HOPE, and UNICEF, Kimberly-Clark aims to expand access to life-changing care in Brazil, Peru, China, India, Indonesia, Vietnam, and the United States. Taken together, these partnerships will work to improve the lives of an estimated 24 million women and girls over the next three years. Experience the full interactive
- 김갑성 기자
- 2025-10-09 21:05
킴벌리클라크, 전 세계 2400만 여성과 소녀를 위한 필수 돌봄 강화 글로벌 파트너십 발표

댈러스, 2025년 10월 9일 -- 킴벌리클라크 코퍼레이션(Kimberly-Clark Corporation)(나스닥: KMB)이 여성과 소녀를 위한 필수 돌봄을 발전시키기 위한 노력을 강화하기 위해 네 가지 강화된 전략적 자선 파트너십을 체결했다. 킴벌리클라크는 베이비투베이비(Baby2Baby), 플랜 인터내셔널(Plan International), 프로젝트 HOPE(Project HOPE), 유니세프(UNICEF)와의 이 새로운 프로그램을 통해 브라질, 페루, 중국, 인도, 인도네시아, 베트남, 미국에서 삶의 변화를 가져올 수 있는 돌봄에 대한 접근성을 확대할 계획이다. 이번 파트너십은 향후 3년간 약 2400만 명의 여성과 소녀들의 삶을 개선하는 데 기여할 것으로 기대된다. 전체 인터랙티브 멀티채널 뉴스 보도는 여기서 확인할 수 있다. https://www.multivu.com/kimberly-clark/9238951-en-kimberly-clark-global-partnerships-women-and-girls 이번 발표는 킴벌리클라크 재단(Kimberly-Clark Foundation)이 최근 전략적 초점을
- 김갑성 기자
- 2025-10-09 21:05
LuX-Valve Plus Approved for Hong Kong-Macao Medicine and Equipment Connect

BEIJING, Oct. 9, 2025 -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company with comprehensive structural heart disease interventional solutions, recently announced that LuX-Valve Plus transjugular tricuspid valve replacement system, the product of its subsidiary Jenscare Scientific (Netherlands) B.V., has been officially approved to be included in the Medical Device Catalog of Hong Kong-Macao Medicine and Equipment Connect, enabling commercial clinical application in designated medical institutions in mainland of
- 김갑성 기자
- 2025-10-09 21:00
Phase 3 Clinical Trial of HANSIZHUANG Plus Chemotherapy Meets Primary Endpoint in Neoadjuvant/Adjuvant Gastric Cancer, Greenlighting Early NDA Submission

[ 메디채널 김갑성 기자 ] The phase 3 clinical trial of HANSIZHUANG for perioperative gastric cancer treatment met its EFS primary endpoint, supporting an early New Drug Application (NDA) submission World-first regimen in gastric cancer that replaces adjuvant chemotherapy with mono-immunotherapy in the perioperative setting The ASTRUM-006 study demonstrated a significant improvement in event-free survival (EFS) and achieved a more than threefold higher pathological complete response (pCR) rate compared with the control arm, unlocking the potential for a cure SHANGHAI, Oct. 9, 2025 -- Sha
- 김갑성 기자
- 2025-10-09 20:50
Field Medical First-in-Human 6-Month Data Selected for Late-Breaking Clinical Trial at VT Symposium 2025

Three sessions feature new outcomes, a live case, and preclinical research with the FieldForce™ Ablation System. CARDIFF-BY-THE-SEA, Calif., and PHILADELPHIA, Oct. 9, 2025 -- Field Medical, Inc., a leader in pulsed field ablation (PFA) technology for ventricular tachycardia (VT), today announced its participation at the 20th Annual International Symposium on Ventricular Arrhythmias (VT Symposium), taking place Oct. 10 –11 in Philadelphia. Field Medical will be featured across three sessions, including first-in-human six-month outcomes from its FieldForce™ Ablatio
- 김갑성 기자
- 2025-10-09 20:33
Health In Tech Showcases Enhanced eDIYBS Platform at SIIA 2025, Accelerating Broker Growth and Market Reach

STUART, Fla.Oct. 9, 2025 -- Health In Tech (Nasdaq: HIT), an Insurtech platform company backed by third-party AI technology, will showcase its groundbreaking Enhanced Do It Yourself Benefit System (eDIYBS) at the upcoming SIIA National Conference, being held October 12–14, 2025 at the JW Marriott Desert Ridge in Phoenix, Arizona. Recently upgraded in September 2025, the platform now supports mid- and large-sized employers (150+ employees), significantly expanding HIT's addressable market. Health In Tech's presence at SIIA represents a strategic opportunity to expa
- 황정호 기자
- 2025-10-09 19:30
Samsung Biologics Introduces Optimized Manufacturing Framework, ExellenS™

ExellenS TM applies optimized facility designs, equipment, and processes across all sites to ensure equivalency and speed ExellenS TM combines the company's commitment to operational excellence with its core manufacturing competencies, guided by standardization, simplification, and scalability ExellenS TM delivers faster tech transfers, rapid approvals, predictable outcomes, and global flexibility for clients INCHEON, South Korea, Oct. 9, 2025 -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today unveiled Exe
- 김갑성 기자
- 2025-10-09 19:00

이전

11 12 13 14 15 16 17 18 19 20

많이 본 기사

최근기사

2025-10-19_SUN

2025-10-18_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 10월 19일 03시 20분